Trials / Completed
CompletedNCT00685399
Safety and Efficacy of AIN457 in Noninfectious Uveitis
An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AIN457 | AIN457 subcutaneous dose |
| DRUG | AIN 457 | AIN457 low dose (i.v) |
| DRUG | AIN457 | AIN457 high dose (i.v) |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2008-05-28
- Last updated
- 2017-07-17
- Results posted
- 2017-07-17
Locations
23 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT00685399. Inclusion in this directory is not an endorsement.